William Blair Investment Management LLC Sells 21,393 Shares of Mirum Pharmaceuticals, Inc. $MIRM

William Blair Investment Management LLC trimmed its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 1.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,383,348 shares of the company’s stock after selling 21,393 shares during the quarter. William Blair Investment Management LLC owned 2.13% of Mirum Pharmaceuticals worth $118,249,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Fisher Asset Management LLC raised its position in shares of Mirum Pharmaceuticals by 137.9% in the 3rd quarter. Fisher Asset Management LLC now owns 196,199 shares of the company’s stock worth $16,771,000 after acquiring an additional 113,723 shares in the last quarter. Nan Fung Trinity HK Ltd. increased its position in shares of Mirum Pharmaceuticals by 1.6% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 222,679 shares of the company’s stock valued at $19,035,000 after acquiring an additional 3,464 shares during the period. Illinois Municipal Retirement Fund purchased a new position in shares of Mirum Pharmaceuticals in the third quarter worth about $1,168,000. Knights of Columbus Asset Advisors LLC raised its position in Mirum Pharmaceuticals by 0.5% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 23,944 shares of the company’s stock worth $2,047,000 after buying an additional 113 shares during the last quarter. Finally, Commonwealth Equity Services LLC lifted its position in Mirum Pharmaceuticals by 10.8% during the third quarter. Commonwealth Equity Services LLC now owns 2,471 shares of the company’s stock valued at $211,000 after purchasing an additional 241 shares during the period.

Insiders Place Their Bets

In other news, CEO Christopher Peetz sold 20,000 shares of the company’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $90.00, for a total transaction of $1,800,000.00. Following the completion of the transaction, the chief executive officer directly owned 206,637 shares of the company’s stock, valued at approximately $18,597,330. This represents a 8.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 658 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $100.00, for a total transaction of $65,800.00. Following the completion of the transaction, the senior vice president owned 616 shares in the company, valued at $61,600. This represents a 51.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 104,825 shares of company stock valued at $10,160,873 in the last ninety days. Insiders own 8.32% of the company’s stock.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $93.99 on Monday. The stock has a market cap of $6.14 billion, a P/E ratio of -6.08 and a beta of 0.75. The company has a current ratio of 2.07, a quick ratio of 1.98 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 12-month low of $63.23 and a 12-month high of $130.00. The business’s fifty day simple moving average is $88.79 and its 200-day simple moving average is $98.41.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.38). Mirum Pharmaceuticals had a negative return on equity of 97.25% and a negative net margin of 134.75%. The company had revenue of $185.72 million for the quarter, compared to analyst estimates of $178.07 million. During the same period in the previous year, the firm earned $0.05 earnings per share. The company’s revenue for the quarter was up 39.6% compared to the same quarter last year. As a group, equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.47 EPS for the current fiscal year.

Analysts Set New Price Targets

MIRM has been the topic of several recent research reports. Royal Bank Of Canada restated an “outperform” rating and issued a $155.00 price objective on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 4th. Raymond James Financial reissued a “strong-buy” rating and set a $189.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 4th. Citizens Jmp raised their price target on shares of Mirum Pharmaceuticals from $144.00 to $167.00 and gave the stock a “market outperform” rating in a research note on Wednesday, November 4th. Robert W. Baird boosted their price objective on Mirum Pharmaceuticals from $123.00 to $130.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. Finally, UBS Group set a $137.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Mirum Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $155.56.

Read Our Latest Stock Analysis on MIRM

Mirum Pharmaceuticals Profile

(Free Report)

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.

Featured Stories

Want to see what other hedge funds are holding MIRM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report).

Institutional Ownership by Quarter for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.